183 related articles for article (PubMed ID: 14609763)
1. [Cell therapy and prostate cancer].
Eymard JC; Bernard J
Bull Cancer; 2003; 90(8-9):734-43. PubMed ID: 14609763
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
[TBL] [Abstract][Full Text] [Related]
3. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
5. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
Harzstark AL; Small EJ
Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based immunotherapy for prostate cancer.
Jähnisch H; Füssel S; Kiessling A; Wehner R; Zastrow S; Bachmann M; Rieber EP; Wirth MP; Schmitz M
Clin Dev Immunol; 2010; 2010():517493. PubMed ID: 21076523
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for prostate cancer.
Fong L; Small EJ
Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412
[TBL] [Abstract][Full Text] [Related]
11. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Thara E; Dorff TB; Pinski JK; Quinn DI
Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
[TBL] [Abstract][Full Text] [Related]
13. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.
Fishman M
Expert Opin Biol Ther; 2009 Dec; 9(12):1565-75. PubMed ID: 19916735
[TBL] [Abstract][Full Text] [Related]
14. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW; Sacks N
Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
18. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
